Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics Inc (NQ: ARQT )

20.61 -1.53 (-6.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,837,695
Open 22.44
Bid (Size) 19.80 (10)
Ask (Size) 45.00 (2)
Prev. Close 22.14
Today's Range 20.50 - 22.97
52wk Range 13.59 - 27.88
Shares Outstanding 50,241,789
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Mizuho Sees Buying Opportunity Despite Weakness In This Skin-Disease Focused Stock
Mizuho remains bullish on Arcutis Biotherapeutics Inc (NASDAQ: ARQT). It sees buying opportunity in the weakness as the company heads into 2H of 2022 with four potentially transformative catalysts for... 
Via Benzinga
88 Biggest Movers From Yesterday
Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) shares jumped 118.2% to close at $0.2950 on Wednesday as the company announced it increased retail distribution across Canada with Loblaw... 
Via Benzinga

Performance

YTD
-9.57%
-9.57%
1 Month
+4.83%
+4.83%
3 Month
+18.18%
+18.18%
6 Month
+1.93%
+1.93%
1 Year
-24.75%
-24.75%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Arcutis Secures $225M Debt Financing To Fund Potential Launch Of Roflumilast
Via Benzinga
Arcutis' Roflumilast Cream For Psoriasis Goes Under FDA Review
Via Benzinga
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
Via Benzinga
5 Stocks To Watch For December 23, 2021
Via Benzinga
Is Now the Time to Bet on Arcutis Biotherapeutics?
Via The Motley Fool
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Via Benzinga
Exposures COVID-19
Arcutis Stops ARQ-252 Vitiligo Trial After Formulation-Related Observations In Chronic Hand Eczema Study
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2021
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 27, 2021
Via Benzinga
55 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
38 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Arcutis' Roflumilast Foam Improves Scalp, Body Psoriasis As Early As Two Weeks After Treatment Initiation
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.